Scarica l'app Stockscreener
0.57
2.40%
-0.014
Precedente Chiudi:
$0.584
Aprire:
$0.58
Volume 24 ore:
6,021
Relative Volume:
0.02
Capitalizzazione di mercato:
$55.66M
Reddito:
$1.29M
Utile/perdita netta:
$-29.87M
Rapporto P/E:
-1.5833
EPS:
-0.36
Flusso di cassa netto:
$-14.70M
1 W Prestazione:
-6.17%
1M Prestazione:
-15.25%
6M Prestazione:
-0.02%
1 anno Prestazione:
-52.10%
Intervallo 1D:
$0.566
$0.59
Intervallo di 1 settimana:
$0.566
$0.625
Portata 52W:
$0.4301
$1.23
VolitionRX Ltd Stock (VNRX) Company Profile
Nome
VolitionRX Ltd
Settore
Industria
Telefono
646 650 1351
Indirizzo
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Confronta VNRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.57 | 55.66M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
580.20 | 222.07B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
213.25 | 153.63B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
147.84 | 42.00B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
463.58 | 38.47B | 3.84B | 866.24M | 792.60M | 10.37 |
|
IQV
Iqvia Holdings Inc
|
204.34 | 36.80B | 15.32B | 1.41B | 1.96B | 7.62 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-02-01 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-02-17 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-03-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-05-16 | Iniziato | Maxim Group | Buy |
| 2018-05-14 | Reiterato | The Benchmark Company | Buy |
| 2016-09-07 | Reiterato | Rodman & Renshaw | Buy |
| 2016-02-01 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
VolitionRX Ltd Borsa (VNRX) Ultime notizie
Game-Changing Sepsis Detection: 971-Patient Study Validates Revolutionary Blood Test - StockTitan
D. Boral Capital Reiterates Buy Rating for VolitionRx (NYSE:VNRX) - Defense World
VolitionRx reports expanded global reach in 2024 - Investing.com India
VolitionRx's Nu.Q® Vet Cancer Test Hits Major Milestone: 110,000+ Tests Sold Across 20 Countries - StockTitan
VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com - Defense World
StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - Defense World
VolitionRx CEO Cameron John Reynolds acquires $79,999 in stock By Investing.com - Investing.com Nigeria
Volitionrx director Innes buys $99,999 in common stock By Investing.com - Investing.com Australia
Volitionrx director Innes buys $99,999 in common stock - Investing.com India
VolitionRx chief scientific officer Micallef acquires $24,999 in stock By Investing.com - Investing.com Australia
VolitionRx CEO Cameron John Reynolds acquires $79,999 in stock - Investing.com
SEC Form 424B5 filed by VolitionRX Limited - Quantisnow
Form 424B5 VOLITIONRX LTD - StreetInsider.com
VolitionRx announces pricing of up to $1.9M registered direct offering - MSN
VolitionRx announces $1.9 million stock sale By Investing.com - Investing.com Australia
VolitionRx Secures $1.9M Financing with Insider Backing, Includes Strategic Warrant Package - StockTitan
VNRX: VolitionRx Reports 3Q 2024 results. Over 110,000 Nu.Q Canine Cancer tests have been sold. Cost cutting continues in a plan to be cash flow neutral in 2025. Management focused on signing licensing deals for Capture-PCR & Nu.Q NETs. - Zacks Small Cap Research
VolitionRx: Big EU Trials On Deck - Investing.com
VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Benchmark Reaffirms Hold Rating for VolitionRx (NYSE:VNRX) - MarketBeat
VolitionRx Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
VolitionRx Limited (AMEX:VNRX) Q3 2024 Earnings Call Transcript - Insider Monkey
VolitionRX: Q3 Earnings Snapshot - New Haven Register
VolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
VolitionRx Posts Strong Q3 Growth and Strategic Advances - TipRanks
Lagoda Investment Management's Strategic Acquisition in Volition - GuruFocus.com
Armistice Capital, LLC Acquires New Stake in VolitionRX Ltd - GuruFocus.com
VolitionRX Ltd Reports Q3 Revenue of $475,000, Missing Estimates of $0.65 Million - GuruFocus.com
VolitionRX Ltd (VNRX) Q3 2024 Earnings Report Preview: What to L - GuruFocus.com
VolitionRx (VNRX) Sets Q3 2024 Earnings Call: Key Executives to Present Financial Results | VNRX Stock News - StockTitan
Volition Appoints Timothy I. Still as Chairman – Company Announcement - Financial Times
VolitionRx (NYSE:VNRX) Now Covered by StockNews.com - Defense World
Abionic’s test enters increasingly competitive sepsis fray - BioWorld Online
VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com - Defense World
Volition to share new 'NETs in sepsis management' data insights at upcoming webinar - Quantisnow
VolitionRx adds Dr. Ethel Rubin to its board By Investing.com - Investing.com South Africa
VolitionRx adds Dr. Ethel Rubin to its board - Investing.com India
Volition Appoints Dr. Ethel Rubin as an Independent Director - Quantisnow
VolitionRx announces executive employment updates - Investing.com India
Agency News | ⚡Tamil Nadu’s Veterinary Varsity Directed by High Court To Consider Transgender Student’s Application - LatestLY
Madras HC directs TN veterinary varsity to not reject transgender's application over identity - Hindustan Times
Madras High Court Orders TN Veterinary University to Accept Transgender Candidate's Application - Law Trend
Don't reject transgender's application over identity HC tells TN veterinary varsity - The Week
Madras High Court Upholds Transgender Rights for Veterinary Course Admissions - Devdiscourse
Volato Facing Class-action WARN Act Lawsuit - Aviation International News
VolitionRX Ltd Azioni (VNRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):